Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 213

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 213
---
ITEM 1.             FINANCIAL STATEMENTS

Dynavax Technologies Corporation

Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)

September 30,2025December 31,2024(unaudited) (Note 1) AssetsCurrent assets:Cash and cash equivalents$160,247 $95,883 Marketable securities available-for-sale487,568 617,951 Accounts receivables, net of allowance for doubtful accounts of $0 and $12,313 at September 30, 2025 and December 31, 2024, respectively72,359 45,281 Other receivables962 1,625 Inventories73,288 70,054 Prepaid expenses and other current assets19,907 18,147 Total current assets814,331 848,941 Property and equipment, net45,855 39,001 Operating lease right-of-use assets19,904 21,608 Goodwill2,199 1,946 Other assets, net of allowance for doubtful accounts of $10,970 at September 30, 202564,217 74,760 Total assets$946,506 $986,256 Liabilities and stockholders’ equityCurrent liabilities:Accounts payable$3,948 $9,061 Accrued research and development6,697 4,310 Accrued liabilities51,889 61,066 Convertible Notes, current portion, net of debt discount of $135 at September 30, 2025 (Note 7)40,073 - Other current liabilities4,232 4,197 Total current liabilities106,839 78,634 Convertible Notes, net of debt discount of $4,034 and $1,646 at September 30, 2025 and December 31, 2024, respectively (Note 7)220,966 223,854 Long-term portion of lease liabilities23,985 26,388 CEPI accrual long-term (Note 6)60,337 60,337 Other long-term liabilities241 244 Total liabilities412,368 389,457 Commitments and contingencies (Note 5)Stockholders’ equity:Preferred stock: $0.001 par value, 5,000 shares authorized at September 30, 2025 and December 31, 2024; zero shares outstanding at September 30